BMRN Articles, BioMarin Pharmaceutical Inc.

Biomarin Pharmaceutical (NASDAQ:BMRN) has outperformed the market over the past 20 years by 6.44% on an annualized basis producing an average annua...

Biomarin Pharmaceutical (NASDAQ:BMRN) has outperformed the market over the past 20 years by 6.65% on an annualized basis producing an average annua...

Disclosed in a recent SEC filing on June 4, MEIER, Board Member at Biomarin Pharmaceutical (NASDAQ:BMRN), made a noteworthy transaction involving t...

These 10 large-cap stocks were the worst performers last week. Are they in your portfolio? NICE Ltd (NASDAQ:NICE) shares tumbled 15...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...

Dennis Slamon, Board Member at Biomarin Pharmaceutical (NASDAQ:BMRN), reported a large exercise of company stock options on March 20, according to ...

HENRY FUCHS, President at Biomarin Pharmaceutical (NASDAQ:BMRN), reported an insider sell on March 7, according to a new SEC filing. What Happened...

Activist investor Elliott Investment Management has taken a significant position in BioMarin Pharmaceutical Inc (NASDAQ: BMRN),...

U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 50 points on Tuesday. Here are some big stocks recording gains in today&...

In its Q3 earnings release, PTC Therapeutics Inc (NASDAQ: PTCT) reported a delay to the planned submission of sepiapterin in ph...